Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi - 14 Apr 2023

Yan X, Qin T J, Li B, Qu S Q, Pan L J, Li F H, Liu N N, Xiao Z J, Xu Z F

Abstract excerpt

Objective: To evaluate the clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm-accelerated phase/blast phase (MPN-AP/BP) . Methods: A total of 67 patients with MPN-AP/BP were enrolled from February 2014 to December 2021 at the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences. Their clinical features and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Blast Crisis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Leukemia, Myeloid, Acute

Share to Myeloproliferative Disorders

Share to Primary Myelofibrosis

Share to Prognosis

Share to Splenomegaly

Source

Open in PubMed Open full text

Identifiers

PMID: 37356995
DOI: 10.3760/cma.j.issn.0253-2727.2023.04.003
PMCID: PMC10282866

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].PMID 37356995Read ↗

Accelerated and blast phase myeloproliferative neoplasms.Semantic proximity Read ↗

[Research status and challenges of advanced myeloproliferative neoplasms].Semantic proximity Read ↗

Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.Semantic proximity Read ↗

Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.Semantic proximity Read ↗

The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms.Semantic proximity Read ↗

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read ↗

Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

Update from the latest WHO classification of MPNs: a user's manual.Semantic proximity Read ↗

Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond.Semantic proximity Read ↗

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.Semantic proximity Read ↗

Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.Semantic proximity Read ↗

A case of a primary myelofibrosis with progression and related literature review of progression phase genetics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.